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Background: Although obesity is still considered a risk factor in the development of cardiovascular disorders,
recent studies suggested that it may also be associated with reduced morbidity and mortality, the so-called “obesity
paradox”. Experimental data on the impact of diabetes, obesity and insulin resistance on myocardial ischaemia/
reperfusion injury are controversial. Similar conflicting data have been reported regarding the effects of ischaemic
preconditioning on ischaemia/reperfusion injury in hearts from such animals. The aim of the present study was to
evaluate the susceptibility to myocardial ischaemia/reperfusion damage in two models of diet-induced obesity as
well as the effect of ischaemic and pharmacological preconditioning on such hearts.
Methods: Three groups of rats were fed with: (i) normal rat chow (controls) (ii) a sucrose-supplemented diet (DIO)
(iii) a high fat diet (HFD). After 16 weeks, rats were sacrificed and isolated hearts perfused in the working mode and
subjected to 35 min regional ischaemia/60 min reperfusion. Endpoints were infarct size and functional recovery.
Infarct size was determined, using tetrazolium staining. Activation of PKB/Akt and ERKp44/p42 (RISK pathway)
during early reperfusion was determined using Western blot. Statistical evaluation was done using ANOVA and the
Bonferroni correction.
Results: Infarct sizes of non-preconditioned hearts from the two obese groups were significantly smaller than
those of the age-matched controls. Ischaemic as well as pharmacological (beta-adrenergic) preconditioning with a
beta2-adrenergic receptor agonist, formoterol, caused a significant reduction in infarct size of the controls, but were
without effect on infarct size of hearts from the obese groups. However, ischaemic as well as beta-preconditioning
caused an improvement in functional performance during reperfusion in all three groups. A clear-cut correlation
between the reduction in infarct size and activation of ERKp44/p42 and PKB/Akt was not observed: The reduction
in infarct size observed in the non-preconditioned hearts from the obese groups was not associated with activation
of the RISK pathway. However, beta-adrenergic preconditioning caused a significant activation of ERKp44/p42, but
not PKB/Akt, in all three groups.
Conclusions: Relatively long-term administration of the two obesity-inducing diets resulted in cardioprotection
against ischaemia/reperfusion damage. Further protection by preconditioning was, however, without effect on
infarct size, while an improvement in functional recovery was observed.
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Obesity is considered to be a serious risk factor in the
development of cardiovascular disorders and is tradition-
ally regarded to impact negatively on the outcome of
myocardial ischaemia. However, despite the evidence for
a higher prevalence of obesity in myocardial ischaemia* Correspondence: alo@sun.ac.za
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unless otherwise stated.patients, a number of recent publications suggested that
obesity in humans with ischaemic heart disease is associ-
ated with reduced morbidity and mortality, the so-called
“obesity paradox” [1-3]. The mechanism underlying this
paradox is complex and remains unclear.
Experimental data on the impact of diabetes, obesity
and insulin resistance on myocardial ischaemia/ reperfu-
sion injury (IRI) are also controversial (for reviews see
references [4,5]). In contrast to the vast amount of researchd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Salie et al. Cardiovascular Diabetology 2014, 13:109 Page 2 of 12
http://www.cardiab.com/content/13/1/109done to assess the susceptibility of the heart to ischaemia/
reperfusion damage in types I and II diabetes [4-6], rela-
tively little is known about the effects of obesity per se in
this scenario. Experimental studies reported a variety of
outcomes. For example, in both types I and II diabetes,
hearts have been reported to be more [7-10] or less [11-15]
susceptible to ischaemic damage or not different from
normoglycaemic controls [12,16,17]. In the case of experi-
mental obesity and insulin resistance similar discrepancies
have been reported. A decreased myocardial tolerance
to ischaemia-reperfusion damage was observed in in vivo
[18,19] and ex vivo [20-22] studies using hyperphagia-
induced obese insulin resistant male rats. Similar findings
were reported in other animal models [9,23-26]. Collect-
ively, these studies have shown that an increased infarct size
is associated with concomitant poor functional recovery in
hearts from obese animals compared to the controls. In
contrast to the above, smaller infarcts and improved
functional recovery during reperfusion were reported by
Donner and coworkers [27], using a hyperphagia-induced
obese rat model. A possible explanation for the variation
in susceptibility to ischaemia/reperfusion damage may be
differences in the age of the animals and the duration of
obesity.
Similar conflicting data were obtained when the possibil-
ity of protection of the diabetic heart by ischaemic precon-
ditioning (IPC) was investigated. A few studies reported
preconditioning-mediated protection [28-32] in hearts
from streptozotocin-induced diabetic rats. However, a
considerable number of studies could not demonstrate this
phenomenon, for example, IPC failed to exert protective
effects in Zucker obese [13,26], streptozotocin-induced
diabetic rats [15] and dogs [8]. Using Goto-Kakizaki
rats, Tsang and coworkers [14] reported that diabetic rats
could be preconditioned but required more ischaemia/
reperfusion cycles than controls to induce protection.
Interestingly, failure of myocardial protection by IPC of
streptozotocin-induced diabetic hearts, was attributed to
rapid and extensive loss of ferritin during sustained ischae-
mia after a preceding preconditioning protocol [33].
Despite the plethora of reports on the ability to precon-
dition hearts from diabetic animals [28], as far as we know
no information is available regarding preconditioning-
induced cardioprotection in hyperphagia-induced obesity.
It is now generally accepted that the reduction in in-
jury during reperfusion is characterized by activation of
the reperfusion injury salvage kinase pathway (RISK)
[34,35]. Central to this pathway is activation of the
prosurvival/anti-apoptotic kinase PKB/Akt, which is also
a key enzyme in the insulin signalling pathway [36]. How-
ever, conclusions about the involvement of the RISK path-
way in the response to IPC is hampered by the fact that
not only the models of diabetes differed, but tissue sam-
ples were taken at different times during the experimentalprotocol. For example, samples were collected at the
end of the stabilization time or after the IPC stimulus
[14], during reperfusion after sustained ischaemia [37]
or under baseline conditions [27,38]. Baseline activation
of ERK was found to be increased in streptozotocin-
induced diabetes [38] while both ERKp44/p42 and PKB/
Akt phosphorylation were reported to be lower in rats
on a high fat diet [19]. ERK activation during reperfusion
of streptozotocin-induced diabetic hearts is dependent on
the duration of hyperglycaemia: an increment is seen after
4 weeks followed by a significant reduction after 20 weeks
[37], while PKB/Akt activation showed a similar early
stimulation followed by a reduction [12].
In view of the above-mentioned controversies and
caveats in our current knowledge, the aim of the present
study was to evaluate the susceptibility to ischaemia/re-
perfusion damage in two models of diet-induced obesity
as well as the effect of ischaemic and pharmacological
preconditioning. The most significant observations were
that rats on obesity-inducing diets were characterized by
protection against myocardial ischaemia/reperfusion and
insensitivity to the effects of prior ischaemic or pharma-
cological preconditioning.
Materials and methods
Animals
Age and weight matched male Wistar rats were used in
this study. This study was approved by the Committee for
Ethical Animal Research of the Faculty of Health Sciences,
University of Stellenbosch. The animals were obtained
from the University of Stellenbosch Central Research
Facility. They received water and food ad libitum (light/
dark cycle 6 h00-18 h00; temperature 22°C; humidity
40%). Animals were treated according to the revised South
African National Standard for the Care and Use of
Animals for Scientific Purposes (South African Bureau of
Standards, SANS 10386, 2008). Rats weighing 200 ± 20 g
were divided into three groups: (i) control rats received a
standard commercial rat chow, (ii) diet-induced obese rats
received a sucrose-supplemented diet (DIO), (iii) high
fat diet rats received the DIO diet supplemented with
Holsum cooking fat (HFD). Holsum cooking fat contained
68% saturated fat, 26% mono-unsaturated fat and 5%
poly-unsaturated fat. The animals were fed their respective
diets for 16 weeks. The DIO diet was prepared by addition
of condensed milk and sucrose to the standard rat chow
as described by Pickavance and coworkers [39], while the
HFD was obtained by adding Holsum cooking fat to
the DIO diet. The composition of the diets is summarized
in Table 1.
Chemicals
Routine chemicals (pro analysi) were obtained from
Merck Chemical Co (Cape Town, RSA). Antibodies (ERKp44/
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phospho-PKB/Akt (Ser-473) were purchased from Cell
Signaling Technology, Beverly, MA, USA). Horse-radish
peroxidase labeled secondary antibody, ECL and hyperfilm
were from Amersham, Life Science.
Experimental procedure
After 16 weeks of feeding, non-fasted rats were weighed
and anaesthetized with pentobarbital (30 mg/rat) and
the blood glucose measured using the tail prick method
and a glucometer, as described below. They were then
sacrificed, the blood collected and the hearts removed
for subsequent perfusion in the working mode. The vis-
ceral fat was collected and weighed. In a separate series
of experiments rats were fasted overnight before sacrifice.
The blood was collected, centrifuged, the serum collected
and stored at -80°C for subsequent biochemical analyses.
For evaluation of the baseline RISK pathway, hearts were
freeze-clamped immediately after removal and stored
at −80°C until analysis.
Perfusion technique
Hearts were perfused as described before [40]. Briefly, a
modified Krebs-Henseleit bicarbonate buffer was used,
containing (in mM): NaCl 119; NaHCO3 24.9; KCl 4.7;
KH2PO4 1.2; MgSO4.7H2O 0.59; Na2SO4 0.59; CaCl2
1.25; glucose 10. The buffer was oxygenated with a 95%
oxygen/5%CO2 gas mixture at 37°C.
All perfused hearts were stabilized by retrograde perfu-
sion for 15 min, followed by perfusion for 15 min in the
working mode, during which time the aortic and coronary
flow rates were measured. Thereafter hearts were perfused
for either 20 min retrogradely (non-preconditioned (NPC),
or for 10 min retrogradely, followed by 5 min global
ischaemia/5 min reperfusion (IPC) or for 10 min retro-
gradely, followed by 5 min formoterol (1nM), 5 min wash-
out (beta-preconditioning, BPC). After preconditioning,
hearts were perfused for an additional 10 min in the work-
ing mode to allow measurement of function before the
onset of ischaemia. Hearts were then subjected to 35 min
regional ischaemia (36.5°C) and 60 min reperfusion forTable 1 Composition of diets
Control DI0 HFD
Total fat (g/100 g) 4.8 4.6 11.5
Saturated fat (g/100 g) 0.9 2.8 7.6
Cholesterol (mg/100 g) 2.2 10 13
% protein 17.1 9.4 8.3
% carbohydrate 34.6 46 42
Sucrose (g/100 g) 5.3 23.3 20.4
Control: normal rat chow.
DI0: rat chow + sucrose.
HFD: rat chow + sucrose + cooking fat.
Analyses were done commercially (Microchem, Cape Town).measurements of functional recovery (at 20 and 30 min
reperfusion) and infarct size. Systolic pressure and heart
rate were measured through a side-arm of the aortic
cannula connected to a Viggo-Spectramed pressure trans-
ducer coupled to a computer system.
For evaluation of ERKp44/p42 and PKB/Akt activa-
tion, hearts were stabilized as described above, but sub-
jected to 15 min global ischaemia, followed by 10 min
reperfusion and then freeze-clamped for subsequent
Western blotting.
Determination of infarct size
Myocardial infarct size was determined as described pre-
viously, using tetrazolium staining [41]. Each heart was
cut in 2 mm thick slices. For each slice the left ventricle
area at risk and the infarcted areas were determined
using computerized planimetry (UTHCSA Image Tool
programme, University of Texas Health Science Center
at San Antonio, TX, USA).
Western blot analyses
Hearts from each group were collected either after sacrifice
(baseline) or after 10 min reperfusion following 15 min glo-
bal ischaemia. A so-called negative control, prepared from
an untreated control heart perfused in the Langendorff
mode for 15 min, was included in each blot. Cytosolic
PKB/Akt and ERKp44/p42 were extracted from frozen left
ventricular tissue by pulverization and homogenization in
600–900 μl lysis buffer using a Polytron homogenizer as
described before [42]. Samples were centrifuged at 1000 g
for 10 min to obtain the supernatant which was used for
Western blotting. The protein content was determined
using the Bradford technique [43]. The lysates were diluted
in Laemmli sample buffer. Western blotting was done as
described before [42]. Membranes were routinely stained
with Ponceau red for visualization of proteins and to con-
firm adequate transfer and equal loading. Films were densi-
tometrically analyzed (UN-SCAN-IT™, Silk Scientific Inc,
Orem, Utah, USA). Protein activation was expressed as a
ratio of phospho- to total protein.
For evaluation of activation of ERKp44/p42 and PKB/
Akt during reperfusion, 4–5 hearts were studied in each
series. For comparison purposes, each blot included the
same control and the data obtained from all experimen-
tal groups were expressed as a ratio of the control heart.
Biochemical analyses
Fasting blood glucose was measured using a glucometer
(Gluco PlusTM, distributed by CIPLA DIBCARE, Bellville,
South Africa). Serum insulin levels were determined using
a competitive radioimmunoassay (RIA) (Coat-A-Count®
Insulin, Siemens Healthcare Diagnostic Products Inc.,
LA, USA) according to the manufacturer’s instructions. Fast-
ing serum triglycerides were determined using CardioCheck_
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USA). For this test, 40 μL of fresh blood was collected
and placed on a lipid test strip (PTS PanelsTM; Polymer
Technology City), for measurement of triglycerides.
Statistical analysis
Results were processed using GraphPad Prism statistical
software (versions 5 and 6). All results were expressed as
mean ± standard error of the mean (SEM). For compari-
sons, an analysis of variance (ANOVA), followed by the
Bonferroni correction was applied. A p-value of p < 0.05
was considered significant.
Results
Biometric parameters
Both diets, when given for a period of 16 weeks, caused
significant increases in body weight when compared to
rats receiving normal rat chow (DIO: 12% and HFD:
21%). This was also associated with significant increases
in visceral fat in both groups. Fasting blood glucose
levels were slightly, but significantly higher in the obese
groups, whereas serum triglycerides and insulin levels
were also significantly higher in the DIO and HFD rats
respectively (see Table 2).
Effect of diet on infarct size and functional recovery
Infarct size
The percentage of the area at risk did not differ between
the nine groups and averaged 50.8 ± 0.8. Comparison of
NPC hearts from the control and the two obese groups,
showed that the infarct sizes of DIO and HFD hearts after
exposure to 35 min regional ischaemia, were significantly
smaller than those from rats on a control diet (NDC).
(NDC: 37.69 ± 2.86; DIO 25.31 ± 1.75; HFD 28.81 ± 1.58,
p < 0.05 vs NDC) (Figure 1). IPC as well as BPC caused a
significant lowering in infarct size of hearts from non-diet
controls (NDC) (p < 0.01 respectively) (Figure 2), when
compared to those of NPC hearts.
However, hearts from rats on the DIO and HFD diets
did not respond to the preconditioning protocols: with
both IPC and BPC infarct sizes were similar to those of
their respective NPC groups (Figures 3 and 4).Table 2 Effects of diets on body weight and blood parameter
Non-diet controls (NDC)
Body wt (g) (16) 418 ± 10
Visceral fat (g) (16) 15.9 ± 1.2
Blood glucose (mmol/L)(16) 5.29 ± 0.1
Serum triglyceride (mmol/L) (10) 0.35 ± 0.04
Serum insulin (μIU/ml) (16) 22.02 ± 3.03
Number in brackets indicates number of animals. Animals were fasted overnight.
*p < 0.05 vs NDC.
**p < 0.001 vs NDC.
†p < 0.001 vs DI0.Functional recovery
Parameters of cardiac function during the control
stabilization period were evaluated at two time points:
(i) before the preconditioning protocol and (ii) before
the onset of sustained ischaemia. Since these values did
not differ significantly in the NDC, DIO and HFD
groups, the values obtained at the first time point were
included in Table 3. The parameters of cardiac perform-
ance during this period were similar in the NDC, DIO
and HFD groups and were therefore pooled. Exposure to
35 min regional ischaemia caused a significant reduction
in coronary flow, aortic flow, cardiac output and total
work during reperfusion of NPC hearts from all three
groups when compared to values obtained during the
control period.
Despite the marked differences in the infarct sizes of NPC
hearts (smaller infarcts in DIO and HFD hearts), no signifi-
cant differences were observed when the post-ischaemic
functional parameters of these groups were compared.
However, IPC did improve the mechanical perform-
ance of the NDC and DIO groups as evidenced by the
significant increases in aortic flow, cardiac output and
total work performance during reperfusion, when com-
pared to their respective NPC counterparts. These pa-
rameters also increased during reperfusion of IPC HFD
hearts, but the changes were not significantly different
from those of the corresponding NPC hearts.
In the case of beta-adrenergic preconditioning hearts
from the DIO group showed significant improvement in
aortic flow, cardiac output and total work during reper-
fusion, while the aortic output only was significantly
higher in the NDC group, when compared to their cor-
responding NPC hearts. The improvement in the HFD
hearts was not significant.
Activation of the RISK pathway during reperfusion
For evaluation of the RISK pathway during reperfusion,
preference was given to a model of global (as opposed to
regional) ischaemia, due to the larger amounts of damaged
tissue available. Using this model, we previously showed a
good correlation between infarct size and activation of this
pathway see ref [42]. Thus hearts were freeze-clamped ats
Diet-induced obese rats (DIO) HF diet rats (HFD)
470 ± 18* 507 ± 16*
23.9 ± 1.7** 37.4 ± 2.7**†
6.37 ± 0.4* 6.38 ± 0.18**
1.04 ± 0.17* 0.77 ± 0.07*
58.6 ± 6.4* 37.08 ± 2.83 83*
Figure 1 Effect of diet on infarct size of non-preconditioned
(NPC) hearts after 35 min regional ischaemia/60 min reperfusion.
Abbreviations: NDC: non-diet controls; DIO: diet-induced obesity: HFD:
high fat diet.
Figure 3 Effect of IPC and BPC on infarct size of DIO hearts
after 35 min regional ischaemia/60 min reperfusion.
Abbreviations: see Figures 1 and 2.
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mia. Previous studies from our laboratory showed max-
imal activation of the kinases at this time point.
Comparisons between the three groups were done as
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Figure 2 Effect of ischaemic and beta-preconditioning on
infarct size of NDC after 35 min regional ischaemia/.60 min
reperfusion. Abbreviations: NPC: non-preconditioned; IPC: ischaemic
preconditioning; BPC: beta-preconditioning.PKB/Akt in NPC, IPC and BPC hearts were compared
separately in the NDC, DIO and HFD groups (Figures 5, 6
and 7) (ii) the effect of IPC and BPC on the activation of
the kinases in each group was compared with those
of the corresponding NPC hearts (Figures 8, 9 and 10).
For this purpose values obtained in the blots shown
in Figures 5, 6 and 7 were used. For all blots, the activa-
tion pattern of a control perfused heart was used for
normalization of the data to allow comparison of values
obtained from different blots.Figure 4 Effect of IPC and BPC on infarct size of HFD hearts
after 35 min regional.
Table 3 Effects of diets and preconditioning on myocardial function before and after ischaema
CF AO CO HR PSP TW Number of
hearts
producing
AO during
reperfusion
(ml/min) (ml/min) (ml/min) (beats/min) (mmHg) (mmHg)
Before ischaemia (45) 20.5 ± 0.5 37.6 ± 1.0 58.2 ± 1.1 257 ± 4 92 ± 1 11.6 ± 0.39
After ischaemia
NDC NPC 9.1 ± 4.1* 4.8 ± 2.9*** 13.9 ± 6.8* 167 ± 68 49 ± 20 3.09 ± 1.31* 2/5
IPC 15.2 ± 0.8 23.2 ± 2.3*† 38.4 ± 3.0*† 301 ± 34 83 ± 2 7.49 ± 0.86† 5/5
BPC 16.3 ± 1.0 16.8 ± 4.7**† 33.5 ± 6.0* 252 ± 18 85 ± 3 6.58 ± 1.35 5/5
DI0 NPC 6.4 ± 4.1** 4.0 ± 2.5*** 10.4 ± 6.6* 96 ± 59 32 ± 20* 1.88 ± 1.21*** 3/5
IPC 15.2 ± 4.1 20.0 ± 5.2**† 35.2 ± 1.1*† 211 ± 53 71 ± 18 7.07 ± 1.78† 4/5
BPC 15.8 ± 1.2 15.2 ± 2.3**† 31 ± 3.3*† 278 ± 13 85 ± 2 5.75 ± 0.81† 5/5
HFD NPC 8.8 ± 3.7* 4.8 ± 2.3*** 14.4 ± 6.0** 141 ± 58 49 ± 20 2.66 ± 1.09*** 2/5
IPC 13.6 ± 3.5 13.2 ± 5.2*** 26.8 ± 7.8* 210 ± 55 69 ± 17 5.18 ± 1.50* 4/5
BPC 8.7 ± 3.9* 9.0 ± 5.4*** 17.0 ± 8.4** 126 ± 57* 42 ± 19 3.36 ± 1.64** 3/6
Abbreviations: CF Coronary flow, AO Aortic output, CO Cardiac output, HR heart rate, PSP peak systolic pressure, TW total work.
NPC non-preconditioned, IPC ischaemic preconditioning, BPC beta-preconditioning.
Five-six hearts were studied in each series. Values obtained before ischaemia were grouped together.
*p < 0.05 vs Before; **p < 0.01 vs Before; ***p < 0.001 vs Before; †p < 0.05 vs NPC.
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Figure 9 DIO: effect of NPC, IPC and BPC on ERKp44/p42 (A)
and PKB (B) activation. Abbreviations: see Figures 1, 2 and 5.
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DIO groups, with the HFD group showing no activation
of these kinases when reperfused.
However, in the case of beta-adrenergic precondition-
ing, activation of ERKp44/p42 and PKB/Akt was seen in
all three groups, but no significant differences were
observed between the groups (Figure 7A,B).
Comparison of the activation pattern of the RISK
pathway in NPC hearts with those of preconditioned
hearts from each group is shown in Figures 8, 9 and 10.
An IPC protocol had no effect on the activation pattern
of either kinase in all three groups, compared to the
NPC groups. BPC by formoterol caused significant
increases in ERKp44, but not PKB/Akt phosphorylation
(Figures 8, 9 and 10) in all three groups.
Discussion
The hyperphagia-induced model of obesity has been used
by several workers in the past [39], including ourselves[18,20] and is characterized by moderate weight gain, in-
creased serum insulin, triglyceride (see Table 2) and free
fatty acid (data not shown) levels. Contrary to our expec-
tations, addition of the cooking fat Holsum to the DIO
diet did not cause significant changes in the biometric
parameters when compared to the DIO diet alone. Both
diets caused a small but significant increase in blood
glucose levels, although these animals were not diabetic.
Thus the rats show some of the characteristics of the
metabolic syndrome being obese, insulin resistant and
hyperlipidaemic, but not diabetic.
A number of interesting observations were made: (i)
relatively long-term administration of the two obesity-
inducing diets had no effect on the baseline mechanical
performance of isolated working hearts, when compared
with rats fed a control diet (NDC); (ii) the infarct sizes
of NPC hearts subjected to 35 min regional ischaemia,
were significantly lower in the DIO and HFD groups
than in hearts from rats receiving normal rat chow,
suggesting diet-induced cardioprotection; (iii) in contrast
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Figure 10 HFD: effect of NPC, IPC and BPC on ERKp44/p42 (A)
and PKB (B) activation. Abbreviations: see Figures 1, 2 and 5.
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not be further protected against I/R injury by either
prior IPC or BPC, using infarct size as endpoint. The lat-
ter two interventions however caused an improvement
in the functional recovery during reperfusion in the
NDC and DIO groups, but not in the HFD group.
Effect of obesity on baseline contractile function
In contrast to the reported reduction in baseline mech-
anical function in rats receiving a similar high carbohy-
drate diet (DIO) for the same time period (16 weeks)
[20,44], in the present study, hearts from both the DIO
and HFD groups exhibited a mechanical performance
similar to those of the NDC under these conditions
(Table 3). However when administering the same DIO
diet for a period of 32 weeks, Du Toit and coworkers
[27] could no longer detect the contractile dysfunction
and insulin insensitivity as mentioned above [20,44], des-
pite significant increases in body weight and visceraladiposity. Similarly, du Toit and coworkers reported that
a high fat obesogenic diet for 32 weeks had no deleteri-
ous effects on basal myocardial function, whether evalu-
ated in vivo or in vitro [19]. The reasons for these
observations are not clear.
Indications are that changes in myocardial metabolic
patterns may underlie some of the discrepancies re-
ported. For example, the mechanical dysfunction re-
ported in rats fed a Western diet with high fat and
reduced carbohydrates [45], was attributed to impaired
fatty acid oxidation. Indeed, decreased long chain fatty
acid oxidation during reperfusion has been shown to
impair postischaemic recovery in sucrose-diet insulin
resistant hearts [46]. On the other hand, others have
reported that hearts from obese insulin resistant mice
showed well-preserved function when perfused with
palmitate plus insulin [47,48]. Our results, showing no
difference between the baseline function of the NDC
and obese groups, obtained with glucose as the only sub-
strate ex vivo, were surprising in view of the serum lipid
abnormalities present in vivo in both diet groups after
16 weeks (Table 2), which may have predisposed hearts
of obese rats towards fatty acid metabolism. Preliminary
studies, using palmitate (1.2 mM/3%albumin) as sub-
strate, yielded similar results viz a smaller infarct size
and inability to precondition hearts from obese rats
[Lochner A, Genade S: Unpublished observations].
Response to ischaemia/reperfusion
The results obtained suggest that hearts from both obese
groups have developed tolerance against ischaemic dam-
age over a sixteen week period, as demonstrated by
infarct sizes of NPC hearts being significantly lower than
those of hearts from NDC animals (see Figures 1, 2, 3
and 4). The possible existence of a so-called “metabolic
preconditioning” has recently been discussed in a review
by Balakumar [28] and is suggested to occur in the
acutely diabetic myocardium, while the chronically
diabetic myocardium is more susceptible to ischaemic
injury. Increased resistance to ischaemic damage was
also observed in hearts from both obese and lean type 2
diabetic rats [13,31] and rabbits [11].
Interestingly, the degree of functional recovery during
reperfusion after 35 min of regional ischaemia did not
reflect the reduction in infarct size observed in the obese
groups (see Figure 1) and similar values were obtained
in the three NPC groups (Table 3). The reasons for these
findings are not clear yet. The similar functional recover-
ies observed in these three NPC groups may be due to
the presence of stunning during early reperfusion, which
may mask any possible effects of the diet [41]. The acti-
vation patterns of ERKp44/p42 and PKB/Akt during
early reperfusion of hearts from the non-preconditioned
NDC, DIO and HFD groups did not reveal any correlation
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vation of the RISK pathway In fact, the lowest activation
of ERKp44/p42 and PKB/Akt was seen in the HFD NPC
hearts, while their infarct sizes were significantly smaller
than those of the NDC hearts (Figures 1 and 5A,B).
The finding of an increased capacity to tolerate ischae-
mia after 16 weeks of the DIO diet is in contrast to
previous findings in rats on a similar diet [18,20-22].
However, prolonging the period of administration of the
DIO diet from 16 to 32 weeks, also paradoxically im-
proved the tolerance of the hearts to I/R damage [27].
The latter group also reported an increased activation in
baseline PKB/Akt (evaluation of activation during reper-
fusion was not done). In contrast to the DIO study, Du
Toit and coworkers reported a very significant reduction
in ischaemic tolerance in hearts from rats exposed to a
HFD for 32 weeks [19]. This increase in infarct size was
associated with a reduction in basal PKB/Akt and GSK-
3β phosphorylation. However, in the present study base-
line expression and activation of ERKp44/p42 and PKB/
Akt were similar in the three groups studied [Lochner
A, Genade S, Unpublished observations]. The marked
difference between our finding of increased tolerance to
ischaemia in hearts from HFD rats and the findings of
Wensley [19] may be due to the period of diet administra-
tion (16 vs 32 weeks), differences in diet fat and carbohy-
drate contents (the Wensley diet contained higher fat and
carbohydrate contents) as well as differences in activation
of the RISK pathway.
The mechanism whereby moderate obesity and insulin
resistance induces a preconditioned state of the heart is
still unsure. Possibilities include formation of new collat-
erals, as was reported in rats [31] or rabbits [11], a re-
duction in the production in glycolytic metabolites [32]
or a larger response of the KATP channel, as was shown
in diabetic animals [11]. However, the rats used in the
present study were insulin-resistant, but not diabetic.
The high circulating insulin concentrations of the diet
groups (Table 2) may contribute to a permanent precon-
ditioned state. Insulin is known to have a precondition-
ing effect [35]. Another possibility is involvement of the
renin-angiotensin system as was demonstrated in early
overnutrition in rats [25]. This is supported by the finding
that angiotensin-converting enzyme inhibition (ACE-I)
improved pre-ischaemic left ventricular contractility and
restored delayed preconditioning in ob/ob and combined
leptin and LDL receptor-deficient mice [49,50]. However,
role of these factors in the DIO and HFD hearts have to
be investigated.
Effect of preconditioning
Reports on the capacity of IPC to protect hearts from
diabetic animals are contradictory, while its effect on
hyperphagia-induced obesity has not yet been studied. Inaddition to IPC, we also evaluated the effects of BPC by
using a β2 adrenergic receptor agonist, formoterol,
which has been shown to be very effective in eliciting
cardioprotection [42]. Interestingly, in contrast to hearts
from the NDC group, both IPC and BPC had no further
reducing effects on the infarct sizes of DIO and HFD
hearts. This could be due to the fact that these hearts
were already maximally protected by their respective diets.
However, functional recovery did improve, particularly
in the DIO hearts, after both types of preconditioning,
when compared with its respective non-preconditioned
group. This was also reflected in the number of hearts
that were able to produce aortic flow during reperfu-
sion (see Table 3).
Comparison of the effects of IPC and BPC with NPC
on activation of the RISK pathway during reperfusion in
the three groups are shown in Figures 8, 9 and 10. A
clear-cut pattern between a reduction in infarct size as
endpoint and ERK and PKB/Akt activation did not
emerge: The absence of activation of the RISK pathway
by IPC in hearts from the NDC group may be due to
the fact that these hearts were preconditioned by a one
cycle (1×5 min I/5 min reperfusion) only, since most
studies on activation of this pathway were done after
multiple cycles of preconditioning [34,35]. Interestingly,
in all three groups, BPC caused ERKp44/p42 phosphoryl-
ation when compared with NPC hearts (see Figures 8, 9
and 10), but only in the case of NDC was this associated
with a reduction in infarct size. No increased activation of
PKB/Akt was observed in any of the preconditioned
groups, when compared with the corresponding NPC
hearts. Thus activation of the prosurvival kinases during
reperfusion, characteristic of many interventions associ-
ated with cardioprotection [34,35], does not occur in the
cardioprotection associated with obesity. Involvement of
the mitochondrial permeability transition pore in this
scenario also needs to be determined.
Other factors, for example, hypercholesterolemia, hyper-
glycemia or hypertension [28], are unlikely to be the
causes for the failure to precondition the heart, since the
diet groups were not hypercholesterolemic, hypertensive
(data not shown) or hyperglycemic (Table 2). As men-
tioned previously, the role of the RAS system in this
regard needs to be evaluated.
Conclusions
The results obtained in this study demonstrated that
diet-induced obesity for a period of 16 weeks was suffi-
cient to elicit increased tolerance to ischaemia. Since a
clear correlation between infarct size reduction, func-
tional recovery and activation of the RISK pathway did
not emerge, further studies are required to elucidate the
scientific basis for the “obesity paradox”. Indeed recent
studies showed that a high sucrose diet induced profound
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further exploration of mechanisms regulating substrate
metabolism in the insulin resistant heart [46].
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